Brief: Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema
08/10/2025 13:18
Oct 8 (Reuters) - Astria Therapeutics Inc ATXS.O: ASTRIA THERAPEUTICS INITIATES THE PHASE 3 ORBIT-EXPANSE LONG-TERM TRIAL OF NAVENIBART IN PEOPLE WITH HEREDITARY ANGIOEDEMA Source text: ID:nBw7bSlZSa Further company coverage: ATXS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astria Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 07:59 PM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM